StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.74−0.02 (-0.37%)

Close on Nov 19, 2026Market cap $440.70MP/E 42.1Yield –

Arvinas net income

Net income is the profit left for shareholders after every expense, interest and tax.

Arvinas's net income for the twelve months ending Jun 30, 2026 was $9.30M. For fiscal 2025 it was -$80.80M. The highest annual figure on record is -$24.05M in fiscal 2017.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$80.80M–
FY2024Dec 31, 2024-$198.90M–
FY2023Dec 31, 2023-$367.30M–
FY2022Dec 31, 2022-$282.50M–
FY2021Dec 31, 2021-$191.00M–
FY2020Dec 31, 2020-$119.30M–
FY2019Dec 31, 2019-$70.30M–
FY2018Dec 31, 2018-$41.48M–
FY2017Dec 31, 2017-$24.05M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$169.40M–
Q1 FY2026Mar 31, 2026-$57.60M-169.5%
Q4 FY2025Dec 31, 2025-$67.40M–
Q3 FY2025Sep 30, 2025-$35.10M–
Q2 FY2025Jun 30, 2025-$61.20M–
Q1 FY2025Mar 31, 2025$82.90M–
Q4 FY2024Dec 31, 2024-$45.10M–
Q3 FY2024Sep 30, 2024-$49.20M–
Q2 FY2024Jun 30, 2024-$35.20M–
Q1 FY2024Mar 31, 2024-$69.40M–
Q4 FY2023Dec 31, 2023-$154.80M–
Q3 FY2023Sep 30, 2023-$64.00M–
Q2 FY2023Jun 30, 2023-$66.60M–
Q1 FY2023Mar 31, 2023-$81.90M–
Q4 FY2022Dec 31, 2022-$82.90M–
Q3 FY2022Sep 30, 2022-$66.20M–
Q2 FY2022Jun 30, 2022-$70.00M–
Q1 FY2022Mar 31, 2022-$63.40M–
Q4 FY2021Dec 31, 2021-$53.00M–
Q3 FY2021Sep 30, 2021-$46.80M–
Q2 FY2021Jun 30, 2021-$50.30M–
Q1 FY2021Mar 31, 2021-$41.00M–
Q4 FY2020Dec 31, 2020-$41.51M–
Q3 FY2020Sep 30, 2020-$30.82M–
Q2 FY2020Jun 30, 2020-$25.23M–
Q1 FY2020Mar 31, 2020-$21.74M–
Q4 FY2019Dec 31, 2019-$21.05M–
Q3 FY2019Sep 30, 2019-$17.68M–
Q2 FY2019Jun 30, 2019-$17.16M–
Q1 FY2019Mar 31, 2019-$14.40M–
Q4 FY2018Dec 31, 2018-$16.09M–
Q3 FY2018Sep 30, 2018-$13.39M–
Q2 FY2018Jun 30, 2018-$7.85M–
Q1 FY2018Mar 31, 2018-$4.15M–
Q4 FY2017Dec 31, 2017-$4.73M–
Q3 FY2017Sep 30, 2017-$6.40M–
Q2 FY2017Jun 30, 2017-$6.68M–
Q1 FY2017Mar 31, 2017-$6.25M–

More Arvinas figures

See a number that looks wrong?